Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capmatinib in NSCLC with MET Exon 14 Skipping Mutation
NCT03693339Phase 2Unknown
- Sponsor
- Asan Medical Center
- Start
- Oct 2018
- Primary completion
- Jun 2020
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capmatinib in non-small cell lung cancer (NSCLC), sponsored by Asan Medical Center. Primary endpoint: Objective Response Rate. Status: unknown.
02
Drugs
capmatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03693339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693339.